Global Nateglinide Market, By Therapy Type (Monotherapy, Combinational Therapy), Indication (Diabetes, Obesity, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Nateglinide Market Analysis and Size
The global nateglinide market is expected to witness significant growth during the forecast period. Nateglinide is widely metabolized in the liver and excreted in urine (83%) and feces (10%). Major metabolites retain less activity than the parent compound. The rise in the cases of diabetes diseases across the world and the vulnerable aging population, as this population is at high risk of developing metabolic disorders, would influence the demand of nateglinide. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global nateglinide market in the forecast period 2022-2029. The global nateglinide market is tend to have a healthy CAGR in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Nateglinide is commercialized under the brand name of Starlix. It is an oral antihyperglycemic drugs that is widely used for the treatment of diabetes. Nateglinide lowers down the number of glucose levels in the blood by stimulating insulin secretion from the pancreas. It belongs to the meglitinide class of short-acting insulin secretagogues. It is specifically used for the treatment of non-insulin-dependent diabetes mellitus. This agent acts by binding to β cells of the pancreas to stimulate and regulate insulin release.
Nateglinide Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Therapy Type (Monotherapy, Combinational Therapy), Indication (Diabetes, Obesity, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Dr. Reddy’s Laboratories Ltd (India), Zydus Group (India), Nivagen Pharmaceuticals. (U.S.)
|
|
Market Opportunities
|
|
Global Nateglinide Market Dynamics
Drivers
- Increase in the prevalence of diabetes
As per the reports of International Diabetes Federation (IDF), the adult diabetes population is approximately 537 million in 2021, and this number is rising high to 643 million in 2030. Many factors such as obesity, unhealthy diet, and physical inactivity are increasing the cases of Type 1 and Type 2 diabetes cases. The increasing prevalence of diabetic patients are indications of the increasing usage of meglinitides.
- Increase in Obesity
As per the records of the WHO, global occurrence of obesity has nearly tripled since 1975. In 2016, over 1.9 billion adults, 18 years and older, were overweight. Of these, over 650 million were obese. 39% of adults aged 18 years and over were overweight in 2016, and 13% were obese. Obesity can lead to many CVDs and other diseases and in return increases the use of these agents.This boosts the market growth.
Opportunities
- Increasing in Elderly Population
As per the reports of European Society of Cardiology, the total disease burden approximately was around 39.7% due to increasing population growth and ageing. Increase in geriatric population has boosted to significant diabetes burden.
- Increasing Demand for Retail Pharmacies
The increase in the number of nateglinide drugs delivered through retail pharmacies and the rise in the number of retail pharmacies in highly economic countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Lack of Awareness
The lack of awareness among patients and doctors about the Nateglinide is a major restraint. The underdeveloped and developing countries are unaware of rare conditions such as Nateglinide. Many mix this condition with depression, anxiety and bipolar disorders. However, no proper treatment for the disorder deteriorates the emotional status and needs of the patient. Much more research and awareness about these rare diseases are required in many counties.
- High Cost
The huge expenditure associated with these agents surely hamper the market growth. These antihyperglycemic drugs are of high cost and the price is increasing with each passing decade. Thus, this factor hamper the market growth.
- Lack of Proper Medication
Lack of appropriate medications and treatment is expected to increase this medical condition's effects. According to the market analysis, less awareness can lead to a small adoption rate of Olanzapine drugs. Thus, these factors can restrict the total demand for the nateglinide market during the forecast period.
This global nateglinide market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global nateglinide market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Nateglinide Market
The Covid-19 pandemic negatively impacted the global nateglinide market because the utmost priority was given to Covid-19 patients for treatment. Diabetes and uncontrolled hyperglycemia are poorly associated with patients having COVID-19, including an increased risk of severe illness or death. Thus, the COVID-19 outbreak increased the nateglinide market's growth globally.
Global Nateglinide Market Scope
The global nateglinide market is segmented on the basis of therapy type, indication, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapy Type
- Monotherapy
- Combinational Therapy
Indication
- Diabetes
- Obesity
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Nateglinide Market Regional Analysis/Insights
The global nateglinide market is analysed and market size insights and trends are provided by therapy type, indication, distribution channel and end-user as referenced above.
The major countries covered in the global nateglinide market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing the highest growth for the global nateglinide market throughout the forecasted period due to the increase’s cases of cardiovascular diseases and rapidly aging population.
North America dominates the market due to the increase prevalence of diabetes disorders and advanced healthcare facilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Nateglinide Market Share Analysis
The global nateglinide market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global nateglinide market.
Key players operating in the global nateglinide market include:
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Dr. Reddy's Laboratories Ltd (India)
- Endo International plc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sun Pharmaceutical Industries Ltd (India)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Lupin (India)
- Cipla Inc (India)
- Aurobindo Pharma (India)
- Zydus Group (India)
- Nivagen Pharmaceuticals. (U.S.)
SKU-